

GREENLEE, WINNER and SULLIVAN, P.C.

4875 Peal East Circle, Suite 200
Boulder, Colorado 80301 USA
Telephone (303) 499-8080
Fax (303) 499-8089

RECEIVED
CENTRAL FAX CENTER

JAN 23 2006

FACSIMILE COVER SHEET

DATE: January 23, 2006

TOTAL NO. PAGES 5
(incl. cover sheet):

TO: COMMISSIONER FOR PATENTS
UNITED STATES PATENT & TRADEMARK OFFICE

FACSIMILE NUMBER: 571-273-8300

FROM: Sally A. Sullivan

RE: Our Docket No. 36-02

IF TRANSMISSION IS UNCLEAR, PLEASE TELEPHONE (303) 499-8080
IMMEDIATELY AND ASK FOR Bobbye.

COMMENTS:

Please refer to the attached Response to Restriction Requirement.

CONFIDENTIALITY NOTICE

This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged and confidential. If the reader of this message is not the intended recipient or the agent responsible for delivering the message to the intended recipient, you are hereby notified that any disclosing, copying, distributing or the taking of any action in reliance on the contents of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone (call collect) and return the original to us at the above address via the postal service. Thank you.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Application No. : 10/680,076
Confirmation No. : 9942
Applicant: : Thomas Bell
Filed: : October 6, 2003
Examiner: : Coleman, Brenda L..
Group Art Unit : 1624
For: Triaza Compound Immuno-
regularatory Agents
Docket No. : 36-02
Customer No. : 23713

RECEIVED
CENTRAL FAX CENTER

JAN 23 2006

CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being facsimile
transmitted to the U.S. Patent and Trademark Office on
January 23, 2006 FAX No. (571)273-8300


Bobbie Simon

Response to Restriction Requirement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please enter the following response to the Restriction Requirement mailed
December 21, 2005.

The claims in this case have not been amended.

Remarks begin on page 2 of this paper.